Aluminium hydroxide

CLINICAL USE

Phosphate binding agent

Antacid

DOSE IN NORMAL RENAL FUNCTION

Phosphate binder: 4–20 capsules daily in divided doses

Antacid: 1 capsule 4 times daily and at bedtime

PHARMACOKINETICS

Molecular weight : 78

%Protein binding : 70–90

%Excreted unchanged in urine : No data

Volume of distribution (L/kg) : No data

half-life – normal/ESRD (hrs) : No data

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD : Unknown dialysability. Dose as in normal renal function

HD : Unknown dialysability. Dose as in normal renal function

HDF/high flux : Unknown dialysability. Dose as in normal renal function

CAV/VVHD : Unknown dialysability. Dose as in normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs None known

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

K/DOQI guidelines caution that CKD 5 patients on chronic therapy may develop aluminium toxicity; therefore best avoided in all but short-term therapy (calcium carbonate, calcium acetate, lanthanum or sevelamer are used in chronic therapy)

Take/administer with or immediately before meals

In patients undergoing chronic therapy with aluminium hydroxide, serum aluminium levels should be monitored

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home